Long-term outcome in patients with takotsubo syndrome : A single center study from Vienna.

BACKGROUND: There is an increasing amount of evidence suggesting multiple fatal complications in takotsubo syndrome; however, findings on the long-term outcome are scarce and show inconsistent evidence. METHODS: This is a single center study of long-term prognosis in takotsubo patients admitted to the Klinik Ottakring, Vienna, Austria, from September 2006 to August 2019. We investigated the clinical features, prognostic factors and outcome of patients with takotsubo syndrome. Furthermore, survivors and non-survivors and patients with a different cause of death were compared. RESULTS: Overall, 147 patients were included in the study and 49 takotsubo patients (33.3%) died during the follow-up, with a median of 126 months. The most common cause of death was a non-cardiac cause (71.4% of all deaths), especially malignancies (26.5% of all deaths). Moreover, non-survivors were older and more often men with more comorbidities (chronic kidney disease, malignancy). Patients who died because of cardiovascular disease were older and more often women than patients who died due to non-cardiovascular cause. Adjusted analysis showed no feature of an independent predictor of cardiovascular mortality for takotsubo patients. Female gender (HR = 0.32, CI: 0.16-0.64, p < 0.001), cancer (HR = 2.35, CI: 1.15-4.8, p = 0.019) and chronic kidney disease (HR = 2.61, CI: 1.11-6.14, p = 0.028) showed to be independent predictors of non-cardiovascular mortality. CONCLUSION: Long-term prognosis of takotsubo patients is not favorable, mainly due to noncardiac comorbidities. Hence, consequent outpatient care in regular intervals after a takotsubo event based on risk factor control and early detection of malignancies seems justified.

Generalized EPID calibration for in vivo transit dosimetry.

Many researchers are studying new in vivo dosimetry methods based on the use of Elelctronic portal imaging devices (EPIDs) that are simple and efficient in their daily use. However the need of time consuming implementation measurements with solid water phantoms for the in vivo dosimetry implementation can discourage someone in their use. In this paper a procedure has been proposed to calibrate aSi EPIDs for in vivo transit dosimetry. The dosimetric equivalence of three aSi Varian EPIDs has been investigated in terms of signal reproducibility and long term stability, signal linearity with MU and dose per pulse and signal dependence on the field dimensions. The signal reproducibility was within ± 0.5% (2SD), while the long term signal stability has been maintained well within ± 2%. The signal linearity with the monitor units (MU) was within ± 2% and within ± 0.5% for the EPIDs controlled by the IAS 2, and IAS 3 respectively. In particular it was verified that the correction factor for the signal linearity with the monitor units, k(lin), is independent of the beam quality, and the dose per pulse absorbed by the EPID. For 6, 10 and 15 MV photon beams, a generalized set of correlation functions F(TPR,w,L) and empirical factors f(TPR,d,L) as a function of the Tissue Phantom Ratio (TPR), the phantom thickness, w, the square field side, L, and the distance, d, between the phantom mid-plane and the isocentre were determined to reconstruct the isocenter dose. The tolerance levels of the present in vivo dosimetry method ranged between ± 5% and ± 6% depending on the tumor body location. In conclusion, the procedure proposed, that use generalized correlation functions, reduces the effort for the in vivo dosimetry method implementation for those photon beams with TPR within ± 0.3% as respect those here used.

A generalized calibration procedure for in vivo transit dosimetry using siemens electronic portal imaging devices.

A practical and accurate generalized in vivo dosimetry procedure has been implemented for Siemens linacs supplying 6, 10, and 15 MV photon beams, equipped with aSi electronic portal imaging devices (EPIDs). The in vivo dosimetry method makes use of correlation ratios between EPID transit signal, s (t) (0) (TPR,w,L), and phantom mid-plane dose, D (0)(TPR,w,L), as functions of phantom thickness, w, square field dimensions, L, and tissue-phantom ratio TPR(20,10). The s (t) (0) (TPR,w,L) and D (0)(TPR,w,L) values were defined to be independent of the EPID sensitivity and monitor unit calibration, while their dependence on TPR(20,10) was investigated to determine a set of generalized correlation ratios to be used for beams with TPR(20,10) falling in the examined range. This way, other radiotherapy centers can use the method with no need to locally perform the whole set of measurements in solid water phantoms, required to implement it. Tolerance levels for 3D conformal treatments, ranging between ±5 and ±6% according to tumor type and location, were estimated for comparison purposes between reconstructed isocenter dose, D (iso), and treatment planning system (TPS) computed dose D (iso,TPS). Finally a dedicated software, interfaceable with record and verify (R&V) systems used in the centers, was developed to obtain in vivo dosimetry results in less than 2 min after beam delivery.

Correlation functions for Elekta aSi EPIDs used as transit dosimeter for open fields.

In-vivo dosimetry techniques are currently being applied only by a few Centers because they require time-consuming implementation measurements, and workload for detector positioning and data analysis. The transit in-vivo dosimetry performed by the electronic portal imaging device (EPID) avoids the problem of solid-state detector positioning on the patient. Moreover, the dosimetric characterization of the recent Elekta aSi EPIDs in terms of signal stability and linearity make these detectors useful for the transit in-vivo dosimetry with 6, 10 and 15 MV photon beams. However, the implementation of the EPID transit dosimetry requires several measurements. Recently, the present authors have developed an in-vivo dosimetry method for 3D CRT based on correlation functions defined by the ratios between the transit signal, st (w,L), by the EPID and the phantom midplane dose, Dm(w,L), at the source to axis distance (SAD) as a function of the phantom thickness, w, and the square field dimensions, L. When the phantom midplane was positioned at distance, d, from the SAD, the ratios st(w,L)/s't(d,w,L) were used to take into account the variation of the scattered photon contributions on the EPID as a function of d and L.The aim of this paper is the implementation of a procedure that uses generalized correlation functions obtained by nine Elekta Precise linac beams. The procedure can be used by other Elekta Precise linacs equipped with the same aSi EPIDs, assuming the stabilities of the beam output factors and the EPID signals. The procedure here reported avoids measurements in solid water equivalent phantoms needed to implement the in-vivo dosimetry method in the radiotherapy department. A tolerance level ranging between ± 5% and ± 6% (depending on the type of tumor) was estimated for the comparison between the reconstructed isocenter dose, Diso, and the computed dose, Diso,TPS, by the treatment planning system (TPS).